Drugs@FDA document
CYSTARAN Letter · NDA 200740 SUPPL-3
Drugs@FDA document · LEADIANT BIOSCI INC · Feb 28, 2022
Key facts
| Drug name | CYSTARAN |
|---|---|
| Document type | Letter |
| Application | NDA200740 |
| Submission | SUPPL-3 |
| Company | LEADIANT BIOSCI INC |
| Document date | Feb 28, 2022 |
| FDA document | accessdata.fda.gov |
At a glance
- Manufacturing (CMC)-Facility Document categories
- 10–99 Documents for this application
- 1–9 USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: